Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyThoracic TumorsTumor, regardless of entityDiseaseBreast CancerLung Carcinoma, Non-Small CellLung Carcinoma, Small CellTumor, Various OrgansSubgroupICD10C34.-C50.-MeSHBreast NeoplasmsSmall Cell Lung CarcinomaSequenceChemotherapyChemo-substanceCisplatinHydrocortisoneMitoxantroneThiotepaChemo-substanceCisplatinHydrocortisoneMitoxantroneThiotepaChemo-substanceCisplatinHydrocortisoneMitoxantroneThiotepaChemo-substanceCisplatinHydrocortisoneMitoxantroneThiotepaNo. Substances12 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksCardiotoxicityEmetogenicityLeukopeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorMaisch BMartinoni A Musch EDiseaseMaligner Perikarderguss, hämodynamisch relevantOriginAllgemeine Innere Medizin, Marienhospital Bottrop, GermanyCardiology Unit, Milan, ItalyDepartment of Internal Medicine-Cardiology, Philipps University, Marburg, GermanyProtocols in Revision 3 protocols foundProtocols under revision.Cisplatin 30, Tumor, Various Organs (PID2371 V1.0)Mitoxantrone 20, Tumor, Various Organs (PID2370 V1.0)Thiotepa 15 / Hydrocortisone 30, Tumor, Various Organs (PID2372 V1.0)
